Prometheus Biosciences RXDX Stock
Prometheus Biosciences Price Chart
Prometheus Biosciences RXDX Financial and Trading Overview
Prometheus Biosciences stock price | 199.92 USD |
Previous Close | 199.74 USD |
Open | 199.68 USD |
Bid | 199.94 USD x 1800 |
Ask | 199.95 USD x 800 |
Day's Range | 199.92 - 199.96 USD |
52 Week Range | 24.32 - 199.98 USD |
Volume | 1.79M USD |
Avg. Volume | 1.24M USD |
Market Cap | 9.56B USD |
Beta (5Y Monthly) | -0.485651 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 194.29 USD |
RXDX Valuation Measures
Enterprise Value | 8.87B USD |
Trailing P/E | N/A |
Forward P/E | -47.486935 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2392.6194 |
Price/Book (mrq) | 13.673483 |
Enterprise Value/Revenue | 2219.088 |
Enterprise Value/EBITDA | -54.856 |
Trading Information
Prometheus Biosciences Stock Price History
Beta (5Y Monthly) | -0.485651 |
52-Week Change | 684.30% |
S&P500 52-Week Change | 20.43% |
52 Week High | 199.98 USD |
52 Week Low | 24.32 USD |
50-Day Moving Average | 184.19 USD |
200-Day Moving Average | 109.6 USD |
RXDX Share Statistics
Avg. Volume (3 month) | 1.24M USD |
Avg. Daily Volume (10-Days) | 1.06M USD |
Shares Outstanding | 47.81M |
Float | 33.23M |
Short Ratio | 3.97 |
% Held by Insiders | 16.60% |
% Held by Institutions | 81.01% |
Shares Short | 4.68M |
Short % of Float | 9.79% |
Short % of Shares Outstanding | 9.77% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -4064.73% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -20.057% |
Return on Equity (ttm) | -33.29% |
Income Statement
Revenue (ttm) | 4M USD |
Revenue Per Share (ttm) | 0.09 USD |
Quarterly Revenue Growth (yoy) | -71.79% |
Gross Profit (ttm) | -106039000 USD |
EBITDA | -161611008 USD |
Net Income Avi to Common (ttm) | -150562000 USD |
Diluted EPS (ttm) | -3.54 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 713.67M USD |
Total Cash Per Share (mrq) | 14.93 USD |
Total Debt (mrq) | 29.46M USD |
Total Debt/Equity (mrq) | 4.22 USD |
Current Ratio (mrq) | 37.56 |
Book Value Per Share (mrq) | 14.621 |
Cash Flow Statement
Operating Cash Flow (ttm) | -133410000 USD |
Levered Free Cash Flow (ttm) | -81391248 USD |
Profile of Prometheus Biosciences
Country | United States |
State | CA |
City | San Diego |
Address | 3050 Science Park Road |
ZIP | 92121 |
Phone | 858 422 4300 |
Website | https://www.prometheusbiosciences.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 97 |
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Q&A For Prometheus Biosciences Stock
What is a current RXDX stock price?
Prometheus Biosciences RXDX stock price today per share is 199.92 USD.
How to purchase Prometheus Biosciences stock?
You can buy RXDX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Prometheus Biosciences?
The stock symbol or ticker of Prometheus Biosciences is RXDX.
Which industry does the Prometheus Biosciences company belong to?
The Prometheus Biosciences industry is Biotechnology.
How many shares does Prometheus Biosciences have in circulation?
The max supply of Prometheus Biosciences shares is 47.81M.
What is Prometheus Biosciences Price to Earnings Ratio (PE Ratio)?
Prometheus Biosciences PE Ratio is 0.00000000 now.
What was Prometheus Biosciences earnings per share over the trailing 12 months (TTM)?
Prometheus Biosciences EPS is 0 USD over the trailing 12 months.
Which sector does the Prometheus Biosciences company belong to?
The Prometheus Biosciences sector is Healthcare.
Prometheus Biosciences RXDX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
Nasdaq US 700 Small Cap Index NQUS700SC | 2060.1 USD — |
-1.99
|
— — | 2051.95 USD — | 2093.4 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
Nasdaq US Smart Pharmaceuticals NQSSPH | 1383.38 USD — |
-2.07
|
— — | 1380.57 USD — | 1408.57 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2541.54 USD — |
-1.89
|
— — | 2531.95 USD — | 2572.66 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}